Here are the Form 4 insider transactions from Filana Therapeutics, Inc. (FLNA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow FLNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FLNA filings page.
Filana Therapeutics, Inc. (FLNA) President & CEO Richard Barry reported two purchases of common stock held indirectly by trust: 206,813 shares on September 29, 2026, at a $0.90 weighted average price, and 100,000 shares on September 30, 2026, at a $0.92 weighted average price. The respective open-market purchase ranges were $0.86–$0.94 and $0.91–$0.93 per share. No Rule 10b5-1 plan is reported.
Filana Therapeutics, Inc. (FLNA) President & CEO Barry Richard reported an indirect purchase through a trust of 93,091 common shares on September 28, 2026. The shares were bought in multiple open market transactions at a weighted average price of $0.84 per share, within a range of $0.82 to $0.85. The reported post-transaction position was 1,031,151 shares held indirectly through a trust. No Rule 10b5-1 plan is reported.